Quetiapine ( DrugBank: Quetiapine )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	5
13	多発性硬化症／視神経脊髄炎	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04373317 (ClinicalTrials.gov)	October 24, 2022	29/4/2020	Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis	CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)	Parkinson's Disease Psychosis	Drug: Pimavanserin;Drug: Quetiapine	VA Office of Research and Development	NULL	Recruiting	40 Years	N/A	All	358	Phase 4	United States
2	NCT05590637 (ClinicalTrials.gov)	April 22, 2022	18/10/2022	Comparing Antipsychotic Medications in LBD Over Time	A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease	Parkinson's Disease Psychosis;Dementia With Lewy Bodies	Drug: Pimavanserin;Drug: Quetiapine	The University of Texas Health Science Center at San Antonio	Alzheimer's Association	Recruiting	N/A	N/A	All	94	Phase 4	United States
3	NCT04164758 (ClinicalTrials.gov)	October 23, 2019	13/11/2019	Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	Parkinson's Disease	Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine	ACADIA Pharmaceuticals Inc.	NULL	Terminated	50 Years	85 Years	All	11	Phase 2	United States
4	EUCTR2004-002608-13-GB (EUCTR)	16/05/2005	19/04/2005	Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease	Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease	Parkinson's Disease with psychosis	Trade Name: Seroquel Product Name: Seroquel Trade Name: Seroquel Product Name: Seroquel	King’s College London & King’s College Hospital	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
5	NCT00043849 (ClinicalTrials.gov)	July 2002	14/8/2002	Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)	Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)	Dementia;Parkinson Disease	Drug: Quetiapine	National Institute on Aging (NIA)	NULL	Completed	50 Years	N/A	Both	60	Phase 4	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02087631 (ClinicalTrials.gov)	December 2014	12/3/2014	Safety and Tolerability of Quetiapine in Multiple Sclerosis	A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Extended-release quetiapine fumarate	University of Calgary	Multiple Sclerosis Society of Canada	Completed	18 Years	65 Years	All	14	Phase 1/Phase 2	Canada